Work

Efficacy and Patient (PT)-Reported Outcomes (PROS) aith Selumetinib (AZD6244, ARRY-142866; SEL) + Docetaxel (DOC) in Kras-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): A Randomized, Phase II Trial

Year: 2012

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33904-1

Authors: P.A. Janne, A.T. Shaw, J.R. Pereira, G. Jeannin, J.F. Vansteenkiste, C. Barrios, F.A. Franke, L. Grinsted, I. Smith, L. Crino

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Centre Hospitalier Universitaire de Clermont-Ferrand, Universitair Ziekenhuis Leuven, KU Leuven, Hospital São Lucas da PUCRS, AstraZeneca (United Kingdom)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2998995302

FWCI: 0.474

Cites:

Cited by: 2

Related to: 10